LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
VSTM
Verastem, Inc.
There isn't enough reported data to score VSTM yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
VSTM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
VSTM's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
VSTM PE Valuation
VSTM has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
VSTM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect VSTM's losses to grow, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus VSTM down 151%.
VSTM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$3.90 | +$0.14 |
| Q2 2024 | -$4.05 | +$0.32 |
| Q1 2024 | -$5.11 | -$0.67 |
| Q4 2023 | -$4.81 | -$0.25 |
| Q3 2023 | -$4.04 | +$0.64 |
| Q2 2023 | -$4.37 | +$0.79 |
| Q1 2023 | -$4.44 | +$0.48 |
| Q4 2022 | -$4.56 | +$0.36 |
VSTM is still losing money, but far less than before: $2.00 per share over the past year, against $24.12 at its worst in late 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over VSTM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over VSTM on profitability, with a higher operating margin.
VSTM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24M | +114% |
| Q2 2026 | $40.1M | +1775% |
| Q2 2025 | $2.1M | -79% |
| Q1 2022 | $2.6M | +158% |
| Q4 2021 | $545K | +7.7% |
| Q3 2021 | $2K | -100% |
| Q2 2021 | $500K | -88% |
| Q1 2021 | $1M | -80% |
VSTM's revenue is recovering but still below its 2020 peak: $24M last quarter, up 114% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -313% | +49 points |
| Q2 2026 | -82% | +1966 points |
| Q1 2026 | -240% | N/A |
| Q4 2025 | -237% | N/A |
| Q3 2025 | -362% | N/A |
| Q2 2025 | -2048% | -1865 points |
| Q2 2024 | -183% | N/A |
| Q1 2022 | -654% | +748 points |
VSTM's operating margin was −313% last quarter, up 49 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
VSTM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2024 | -$23.8M | -$7.2M |
| Q1 2024 | -$28.3M | -$8M |
| Q4 2021 | -$9.9M | +$11.8M |
| Q3 2021 | -$10.8M | -124% |
| Q1 2021 | -$19.5M | +$14.5M |
| Q4 2020 | -$21.7M | +$15.5M |
VSTM has burned cash in almost every quarter: −$155M over the past year, against −$89M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over VSTM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
VSTM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +1.1M shares |
| 1 year | +37% | +27.2M shares |
| 3 years | +505% | +84.5M shares |
| 5 years | +615% | +87.1M shares |
| Available history | +1492% | +94.9M shares |
VSTM has 101M diluted shares, up 37% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
VSTM Net Leverage
VSTM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
VSTM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.0 | Neutral |
| Stochastic | 67.9 | Neutral |
VSTM's weekly RSI is 58 (neutral) and its Stochastic is 68 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
VSTM PE vs Healthcare Sector
VSTM has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over VSTM on trend strength, trading above more of its moving averages.
VSTM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.64 | 2.3% below |
| 20 week MA | $7.37 | 15% above |
| 50 week MA | $6.54 | 29% above |
| 100 week MA | $6.76 | 25% above |
| 200 week MA | $6.95 | 21% above |
VSTM has slipped below its 8-week average, but it's still above the other four, and 21% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over VSTM on returns for 2026, with the stronger performance.
VSTM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.8 | $27.6 | +64% |
| 2021 | $27.6 | $27.7 | +0.4% |
| 2022 | $27.7 | $4.08 | -85% |
| 2023 | $4.08 | $8.14 | +100% |
| 2024 | $8.14 | $3.71 | -54% |
| 2025 | $3.71 | $8.06 | +117% |
| 2026 YTD | $8.06 | $8.44 | +4.7% |
VSTM's yearly returns have swung widely, from +117% in 2025 to −85% in 2022. It's up 4.7% so far in 2026.